SCHEMBL11744136

SCHEMBL11744136

Oc1c(F)cc(Br)cc1Br

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.65
TSHR P16473 1/20 0.65
TDP1 Q9NUW8 1/20 0.65
GABRA1 P14867 2/20 0.56
GABRB1 P18505 2/20 0.56
GABRA2 P47869 1/20 0.56
GABRB2 P47870 1/20 0.56
AKR1C4 P17516 1/20 0.46
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
AKR1C1 Q04828 1/20 0.46
ERN1 O75460 1/20 0.46
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
MAPT P10636 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 2/20 0.42
HTT P42858 2/20 0.42
HPGD P15428 1/20 0.42
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13029 0.86 CYP3A4 (0.50) CYP3A4TSHRTDP1GABRA1GABRB1
Potassium SCHEMBL31361438 0.83 CYP3A4 (0.48) CYP3A4TSHRTDP1GABRA1GABRB1
Lithium SCHEMBL31361451 0.83 CYP3A4 (0.48) CYP3A4TSHRTDP1GABRA1GABRB1
Bromide SCHEMBL4668136 0.83 CYP3A4 (0.48) CYP3A4TSHRTDP1GABRA1GABRB1
SCHEMBL31361467 0.83 CYP3A4 (0.48) CYP3A4TSHRTDP1GABRA1GABRB1
SCHEMBL2050124 0.81 CYP3A4 (0.46) CYP3A4TSHRTDP1GABRA1GABRB1
SCHEMBL18224 0.80 CYP3A4 (1.00) CYP3A4TSHRTDP1GABRA1GABRB1
SCHEMBL1155741 0.79 ERN1 (0.46) CYP3A4TSHRTDP1GABRA1GABRB1
SCHEMBL69509 0.78 CYP3A4 (0.72) CYP3A4TSHRTDP1GABRA1GABRB1
SCHEMBL10546483 0.77 CYP3A4 (0.93) CYP3A4TSHRTDP1GABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed
EP-2921480-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2017-10-11 EP disclosed
US-9777005-B2 Bicyclic heterocyclic compound containing a substituted pyrrole ring TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-10-03 US disclosed
US-9732086-B2 2017-08-15 US disclosed
US-20150307497-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-10-29 US disclosed
EP-2921480-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-09-23 EP disclosed
US-4031249-A TREMATODES, NEMATODES, FASCIOLA SP ICI AUSTRALIA LIMITED (AU) 1977-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307497-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND CHRM1, CHRM2, CHRM4 CYP3A4 469/4885TSHR 185/4885TDP1 3959/4885
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT CYP3A4 2852/4885TSHR 4739/4885TDP1 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.